➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Mallinckrodt
Moodys
Dow
AstraZeneca

Last Updated: May 31, 2020

DrugPatentWatch Database Preview

Aurobindo Pharma Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for AUROBINDO PHARMA, and what generic and branded alternatives to AUROBINDO PHARMA drugs are available?

AUROBINDO PHARMA has three hundred and sixty-four approved drugs.

There are nineteen tentative approvals on AUROBINDO PHARMA drugs.

Summary for Aurobindo Pharma
US Patents:0
Tradenames:278
Ingredients:253
NDAs:364
Patent Litigation for Aurobindo Pharma: See patent lawsuits for Aurobindo Pharma

Drugs and US Patents for Aurobindo Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd FLECAINIDE ACETATE flecainide acetate TABLET;ORAL 202821-002 Nov 3, 2017 AB RX No No   Start Trial   Start Trial
Aurobindo Pharma Ltd CELECOXIB celecoxib CAPSULE;ORAL 206827-004 Feb 1, 2016 AB RX No No   Start Trial   Start Trial
Aurobindo Pharma Ltd QUETIAPINE FUMARATE quetiapine fumarate TABLET;ORAL 091388-001 Mar 27, 2012 AB RX No No   Start Trial   Start Trial
Aurobindo Pharma ALENDRONATE SODIUM alendronate sodium TABLET;ORAL 090124-001 Aug 4, 2008 AB RX No No   Start Trial   Start Trial
Aurobindo Pharma Ltd TRI-LO-MILI ethinyl estradiol; norgestimate TABLET;ORAL-28 205762-001 Nov 4, 2016 AB RX No No   Start Trial   Start Trial
Aurobindo Pharma CEFPROZIL cefprozil FOR SUSPENSION;ORAL 065381-002 Jan 30, 2007 AB RX No No   Start Trial   Start Trial
Aurobindo Pharma Ltd ARMODAFINIL armodafinil TABLET;ORAL 206069-003 Mar 6, 2018 AB RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for AUROBINDO PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
AstraZeneca
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.